Mitchell A. Yakrus
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Mitchell A. Yakrus has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Alfonso J. Rodriguez-Morales
Faculty of Health Sciences, Universidad Científica del Sur, Lima 15067, Peru
1 shared publication Allison McAlister
Centers for Disease Control and Prevention, Atlanta, GA 30329-4027, USA
1 shared publicationAmerindia Aguiar
Collaborative Group of Clinical Infectious Diseases Research, Caracas
1 shared publicationAngela M. Starks
Centers for Disease Control and Prevention, Atlanta, GA 30329-4027, USA
1 shared publicationBeverly Metchock
Centers for Disease Control and Prevention, Atlanta, GA 30329-4027, USA
1 shared publicationCarmen Gamboa
Collaborative Group of Clinical Infectious Diseases Research, Caracas
1 shared publication
Latest Publications
- Open Access
- 8 June 2016
- Published by Wiley in Tuberculosis Research and Treatment
- Vol. 2016, 1-5
Molecular and Growth-Based Drug Susceptibility Testing ofMycobacterium tuberculosisComplex for Ethambutol Resistance in the United States
Ethambutol (EMB) is used as a part of drug regimens for treatment of tuberculosis (TB). Susceptibility ofMycobacterium tuberculosiscomplex (MTBC) isolates to EMB can be discerned by DNA sequencing to detect mutations in theembBgene associated with resistance. US Public Health Laboratories (PHL) primarily use growth-based drug susceptibility test (DST) methods to determine EMB resistance. The Centers for Disease Control and Prevention (CDC) provides a service for molecular detection of drug resistance (MDDR) by DNA sequencing and concurrent growth-based DST using agar proportion. PHL and CDC test results were compared for 211 MTBC samples submitted to CDC from September 2009 through February 2011. Concordance between growth-based DST results from PHL and CDC was 88.2%. A growth-based comparison of 39 samples, where anembBmutation associated with EMB resistance was detected, revealed a higher percentage of EMB resistance by CDC (84.6%) than by PHL (59.0%) which was significant (value = 0.002). Discordance between all growth-based test results from PHL and CDC was also significant (value = 0.003). Most discordance was linked to false susceptibility using the BACTEC™MGIT™960 (MGIT) growth-based system. Our analysis supports coalescing growth-based and molecular results for an informed interpretation of potential EMB resistance.- 8 June 2016
- Published by Wiley in Tuberculosis Research and Treatment
- Vol. 2016, 1-5
Open AccessMolecular and Growth-Based Drug Susceptibility Testing ofMycobacterium tuberculosisComplex for Ethambutol Resistance in the United States
Ethambutol (EMB) is used as a part of drug regimens for treatment of tuberculosis (TB). Susceptibility ofMycobacterium tuberculosiscomplex (MTBC) isolates to EMB can be discerned by DNA sequencing to detect mutations in theembBgene associated with resistance. US Public Health Laboratories (PHL) primarily use growth-based drug susceptibility test (DST) methods to determine EMB resistance. The Centers for Disease Control and Prevention (CDC) provides a service for molecular detection of drug resistance (MDDR) by DNA sequencing and concurrent growth-based DST using agar proportion. PHL and CDC test results were compared for 211 MTBC samples submitted to CDC from September 2009 through February 2011. Concordance between growth-based DST results from PHL and CDC was 88.2%. A growth-based comparison of 39 samples, where anembBmutation associated with EMB resistance was detected, revealed a higher percentage of EMB resistance by CDC (84.6%) than by PHL (59.0%) which was significant (value = 0.002). Discordance between all growth-based test results from PHL and CDC was also significant (value = 0.003). Most discordance was linked to false susceptibility using the BACTEC™MGIT™960 (MGIT) growth-based system. Our analysis supports coalescing growth-based and molecular results for an informed interpretation of potential EMB resistance. - Open Access
- 1 September 2005
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 41 (5) , 759-760
Disseminated Mycobacterium mucogenicum Infection in a Patient with Idiopathic CD4+ T Lymphocytopenia Manifesting as Fever of Unknown Origin
Sir—Infection due to nontuberculous mycobacteria is a matter of increasing interest. Many of these organisms are currently recognized as human pathogens. Members of the Mycobacterium fortuitum complex are the only rapidly growing species that are more frequently isolated as human pathogens [1]. M. fortuitum, Mycobacterium peregrinum, Mycobacterium chelonae, Mycobacterium abscessus, and Mycobacterium mucogenicum (formerly known as “M. chelonae-like organisms”), among other species, are recognized in this complex [2]. M. mucogenicum has been reported to cause peritonitis, posttraumatic skin infection, and catheter sepsis [1, 3, 4], although M. mucogenicum is rarely clinically isolated [1, 3, 4]. For these reasons, we report a patient with idiopathic CD4+ T lymphocytopenia with prolonged fever of unknown origin. The pathogen was identified by culture of bone marrow specimens and molecular biology techniques.
- 1 September 2005
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 41 (5) , 759-760
Open AccessDisseminated Mycobacterium mucogenicum Infection in a Patient with Idiopathic CD4+ T Lymphocytopenia Manifesting as Fever of Unknown Origin
Sir—Infection due to nontuberculous mycobacteria is a matter of increasing interest. Many of these organisms are currently recognized as human pathogens. Members of the Mycobacterium fortuitum complex are the only rapidly growing species that are more frequently isolated as human pathogens [1]. M. fortuitum, Mycobacterium peregrinum, Mycobacterium chelonae, Mycobacterium abscessus, and Mycobacterium mucogenicum (formerly known as “M. chelonae-like organisms”), among other species, are recognized in this complex [2]. M. mucogenicum has been reported to cause peritonitis, posttraumatic skin infection, and catheter sepsis [1, 3, 4], although M. mucogenicum is rarely clinically isolated [1, 3, 4]. For these reasons, we report a patient with idiopathic CD4+ T lymphocytopenia with prolonged fever of unknown origin. The pathogen was identified by culture of bone marrow specimens and molecular biology techniques.